Open AccessPrognostic and tumor-immune infiltration cell signatures in tamoxifen-resistant breast cancers
Author(s) -
Zhenyu Cao,
Ziwei Jin,
Liyun Zeng,
Hongye He,
Qitong Chen,
Qiongyan Zou,
Dengjie Ouyang,
Na Luo,
Yulong Zhang,
Yunchang Yuan,
Wenjun Yi
Publication year - 2021
Publication title -
gland surgery
Language(s) - English
Resource type - Journals
eISSN - 2227-8575
pISSN - 2227-684X
DOI - 10.21037/gs-21-566
Subject(s) - medicine , breast cancer , kegg , oncology , immune system , inflammatory breast cancer , tamoxifen , surgical oncology , gene expression profiling , cancer research , bioinformatics , gene expression , immunology , cancer , biology , gene , transcriptome , genetics
The cumulative risk of distant recurrence of hormone receptor-positive (HR+) breast cancer in the past 20 years has ranged from 22% to 52% after 5 years of endo-therapy. The TNM stage, histological grade, and age are important clinical factors related to recurrence, however the exact mechanism of tamoxifen resistance is still unclear.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom